Four things health execs should know about the oncology pipeline Here’s how you can recognize changes in the oncology pipeline and maximize value related to cancer care. Sharp price increases for cancer drugs October 14, 2016 By Christine Blank A majority of oncology drugs—particularly older cancer drugs—had price hikes in 2015, according to a study. Plus, Ariad Pharmaceuticals raised the price of its chronic myeloid leukemia (CML) drug ponatinib (Iclusig) for the fourth time this year to around $199,000 a year, according to The Street. Are oncology pathways effective? AMCP presenters weigh in October 07, 2016 By Aubrey Westgate Faced with a proliferation of oncology treatments, payers have started using oncology pathways. But what do these programs look like, and are they really working? Oversized cancer drug vials lead to billions in waste annually April 09, 2016 By Tracey Walker As healthcare expenditures rise, researchers from Memorial Sloan Kettering Cancer Center propose ways to reduce waste and cut costs. CVS, Express Scripts plan value-based drug pricing April 03, 2016 By Tracey Walker The approaches reflect a growing number of initiatives meant to tie drug prices to value. Find out more.